

Neuropathic pain is commonly described as numbness, tingling, burning, stabbing, shooting.

- Patients with CKD may experience pain from a variety of causes. They might have neuropathic and/or nociceptive (musculoskeletal) pain.
- Consider using the Follow-up Pain Assessment Tool weekly to monitor effect of pain management.
- See: Pain Patient Handout

Step 1: Adjuvant

1st Line:

Gabapentin 50-100* mg PO nightly. If not effective, it can be further titrated by 100 mg every 7 nights to a maximum of 300 mg PO nightly. It should be taken 2-3 hours before bed due to delay of peak onset. *Note that gabapentin is not commercially available in 50 mg capsules, but can be compounded for patients if the recommended low starting dose is desired*. The most common side effects are drowsiness, dizziness, confusion, and fatigue. Peripheral edema may also be a side effect.

or

Pregabalin 25 mg PO nightly. Titrate by 25 mg every 7 nights to a maximum of 75 mg PO nightly. It should be taken 2 hours before bedtime. Similar to gabapentin, but more expensive and not covered by Seniors' or Basic Alberta Blue Cross plans. Other private plans may cover the cost. Potential side effects are similar to those of gabapentin.

or

Carbamazepine 100 mg PO daily. Titrate by 100 mg every 7 days to a maximum of 1200 mg PO daily. It can be given in divided doses twice daily. May be as effective as gabapentin with fewer side effects.

2nd Line

TCA antidepressant (unless contraindications i.e. conduction abnormalities on ECG, or excess weight gain) For example, amitriptyline (Elavil) 10-25 mg PO daily (max dose 75 mg daily). Titrate by 10-25 mg every week as required.

Is pain now adequately controlled?

Yes: Reassess at least monthly using the Follow-Up Pain Assessment Tool No benefit: STOP Adjuvant and START Non-Opioid/Weak Opioid (Step 2) Some benefit but inadequate: ADD Non-Opioid/Weak Opioid (Step 2)

Step 2: Non-Opioid/Weak Opioid

Due to the pharmacokinetics and pharmacodynamics, there are no recommended weak opioid agents for the treatment of neuropathic pain.

Acetaminophen (Tylenol) 500-1000 mg PO q6-8 hours (max 3 grams/24hrs

Is pain now adequately controlled?

Yes: Reassess at least monthly using the Follow-Up Pain Assessment Tool Inadequate: ADD Strong opioid (Step 3)

Step 3: Strong Opioid

Consider completing an opioid risk tool and order a **bowel routine** (See: Constipation Guideline). Start with low doses and titrate slowly to effect.

Hydromorphone (Dilaudid) 0.5 mg PO q4h (or 0.2 mg SC). Due to the accumulation of metabolites, monitor closely for toxicity.

Fentanyl Transdermal Patch (for controlled pain) 12 mcg/h q72hours. Not recommended in opioid naïve patients (Opioid Conversion Table). Also available SL/SC.

Buprenorphine Transdermal Patch (for controlled pain) 5 mcg/h q7days (Opioid Conversion Table). Is not covered by Alberta Blue Cross. Access may be limited.

Methadone 1-2 mg/day PO (consider referral to Palliative Care; requires specific education and licensing by CPSA.)



Considerations for Opioid Titration:

- Ongoing pain re-assessment is critical.
- Titrate analgesics every 3-7 days as needed and tolerated. Slower titration may be required.
- Titrating up the regular Opioid dose:
 - 1. Add the total amount of opioid used in the last 24 hours (regular and breakthrough doses). Divide the total dose by 6, and prescribe this amount every 4 hours (q4H).

OR

- 2. For ongoing pain exceeding patients pain control targets, adjust as follows:
 - For pain rated 3-6, increase dose of opioid by 25%
 - For pain rated 7-10, increase dose of opioid by 50%
- Breakthrough (PRN) dose prescription: 10% of total 24 hour opioid dose g 1-2 hrs PRN.
- If the patient is also taking benzodiazepines, consider titrating down the dose, while opioids are being increased. If not, titrate opioids more slowly.

Is pain now adequately controlled?

- Yes: Reassess at least monthly using the Follow-Up Pain Assessment Tool
- No: Refer to Palliative Care

Considerations at End of Life: In the last days of life, see the End of Life Pain Algorithm

Conservative Kidney Management Acronym Legend

Acronym:	Intended Meaning:	Acronym:
ATC	Around the Clock	mmol/L
BID	Twice Daily	OTC
CKD	Chronic Kidney Disease	PO
СКМ	Conservative Kidney	PRN
	Management	
COPD	Chronic Obstructive	NSAID
	Pulmonary Disease	
CO2	Carbon Dioxide	q(1-8)d
EOL	End of Life	q(1-8)h
ESA	Erythropoietin Stimulating	q(1-8)weeks
	Agent	
ESKD	End Stage Kidney Disease	QHS
GFR	Glomerular Filtration Rate	RLS
GI	Gastrointestinal	SC
g/L	Grams per litre	SL
HgB	Hemoglobin	SNRI
IN	Intranasal	SSRI
IU	International Units	TCA
IV	Intravenous	TID
kg	Kilogram	>
mcg	Microgram	≥
mg	Milligram	<
mL	Millilitre	≤

Acronym:	Intended Meaning:	
mmol/L	Millimoles per Litre	
OTC	Over the Counter	
PO	By Mouth	
PRN	As Needed	
NSAID	Non-steroidal Anti-	
	inflammatory Drugs	
q(1-8)d	Every (Time Eg, 2) Days	
q(1-8)h	Every (Time Eg, 4) Hours	
q(1-8)weeks	Every (Time Eg. 2) Weeks	
QHS	At Bedtime	
RLS	Restless Leg Syndrome	
SC	Subcutaneous	
SL	Sublingual	
SNRI	Serotonin and	
	Norepinephrine Reuptake Inhibitors	
SSRI	Selective Serotonin	
	Reuptake Inhibitors	
TCA	Tricyclic Antidepressant	
TID	Three Times a Day	
>	Greater Than	
≥	Greater Than or Equal To	
<	Less Than	
≤	Less Than or Equal To	